The Zhitong Finance App learned that on March 29, Edding Group Company Limited (Edding Group Company Limited) submitted a listing application to the main board of the Hong Kong Stock Exchange, with Morgan Stanley and Credit Suisse as co-sponsors. It is worth noting that Yiteng Pharmaceutical submitted a listing application to the main board of the Hong Kong Stock Exchange at the end of September last year.

Yiteng Pharmaceutical is a leading Chinese pharmaceutical company focusing on anti-infections, cardiovascular diseases and respiratory systems. In 2017, 2018, 2019 and 2020, the company's revenue was 1,786 billion yuan (RMB, same below), 1,478 million yuan, 1,774 million yuan and 1,767 million yuan respectively. The profit for the same period was a loss of 38.53 million yuan, a loss of 215 million yuan, net profit of 172 million yuan and 86.9 million yuan respectively. The company's revenue mainly came from pharmaceutical sales.

The company has now established a highly differentiated and diversified product portfolio, including six core products: three commercialized original research brand products and three innovative new drugs under development. Among them, “Stable Credible” and “Sikelow” are anti-infective brands that continue to contribute revenue to Yiteng Pharmaceutical. In 2017, 2018, 2019 and 2020, Stable and Trustworthy generated revenue of 869.9 million yuan, 795.2 million yuan, 726.6 million yuan and 1,0189 million yuan respectively.

Over the same period, Sikelow generated revenue of $389.8 million, $245.1 million, $280.5 million and $477.4 million, respectively. The company acquired fluticasone propionate aerosol inhalation suspension (FPN), a core respiratory system product, from GSK in May 2020. In 2020, FPN generated revenue of 91.8 million yuan.

The company entered the field of cardiovascular disease in 2015, and its authorized core drug under development is Vascepa. The other two core drugs that have been authorized to be introduced are MulpleTA and EDP 125, respectively.